AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportPathAI vs Abridge
PathAI
VS
Abridge
Verdict by Category
Detailed Comparison
Feature
PathAI
Abridge
Pricing
EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division.
Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development.
Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.
EnterpriseAbridge does not publish pricing and sells exclusively through enterprise contracts with health systems and hospital groups; there is no self-serve signup or individual-clinician plan. Third-party market analyses and reseller estimates place costs at roughly $200-$800+ per provider per month depending on integration depth (Epic, Oracle Health, or athenahealth), contract scale, and support level, with some estimates for full enterprise rollouts running $600-$1,200+ per provider per month. Implementation typically includes a multi-week to multi-month pilot and IT integration phase before system-wide deployment.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare Tools
Summary
AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche
Ambient AI that turns clinical conversations into ready-to-sign notes
PathAI Pros & Cons
Pros
- Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
- 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
- 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
- AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
- CLIA-certified lab services for biopharma clinical trial support
- Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
- First AI pathology company recognized as a leader in CB Insights Digital Pathology market map
Cons
- Acquired by Roche in May 2026 — future product roadmap and independent operations may change
- Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
- No self-serve pricing or trial — all engagements are through enterprise procurement
- Requires digital pathology infrastructure (scanners, storage, LIS integration)
- Integration complexity for labs not yet on digital pathology workflows
Abridge Pros & Cons
Pros
- Best in KLAS for Ambient AI two years running (2025 and 2026)
- Largest independent peer-reviewed study of any ambient AI scribe (NEJM AI, 1,300+ clinicians)
- Deep, native Epic integration across Haiku, Canto, and Hyperdrive
- Broad specialty coverage (55+) across outpatient, inpatient, and ED settings
- Strong enterprise security posture: HIPAA, SOC 2 Type II, ISO 27001
Cons
- No public pricing, free trial, or self-serve signup for individual clinicians
- Enterprise-only sales process that can take months to complete
- Reported documentation error rates (including some hallucinated content) still require clinician review
- No built-in patient communication, scheduling, or billing automation
- Not a realistic option for solo practitioners or small group practices